- Home
- RIGL vs BGY Comparison
RIGL vs BGY Comparison
Compare RIGL & BGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- BGY
- Stock Information
- Founded
- RIGL 1996
- BGY 2007
- Country
- RIGL United States
- BGY United States
- Employees
- RIGL N/A
- BGY N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- BGY Trusts Except Educational Religious and Charitable
- Sector
- RIGL Health Care
- BGY Finance
- Exchange
- RIGL Nasdaq
- BGY Nasdaq
- Market Cap
- RIGL 486.4M
- BGY 539.7M
- IPO Year
- RIGL 2000
- BGY N/A
- Fundamental
- Price
- RIGL $17.09
- BGY $5.31
- Analyst Decision
- RIGL Buy
- BGY
- Analyst Count
- RIGL 5
- BGY 0
- Target Price
- RIGL $34.80
- BGY N/A
- AVG Volume (30 Days)
- RIGL 203.8K
- BGY 208.4K
- Earning Date
- RIGL 11-07-2024
- BGY 01-01-0001
- Dividend Yield
- RIGL N/A
- BGY 7.41%
- EPS Growth
- RIGL N/A
- BGY N/A
- EPS
- RIGL 0.22
- BGY N/A
- Revenue
- RIGL $157,374,000.00
- BGY N/A
- Revenue This Year
- RIGL $48.98
- BGY N/A
- Revenue Next Year
- RIGL $14.43
- BGY N/A
- P/E Ratio
- RIGL $77.18
- BGY N/A
- Revenue Growth
- RIGL 21.65
- BGY N/A
- 52 Week Low
- RIGL $7.48
- BGY $4.68
- 52 Week High
- RIGL $29.82
- BGY $5.66
- Technical
- Relative Strength Index (RSI)
- RIGL 30.82
- BGY 36.81
- Support Level
- RIGL $16.68
- BGY $5.52
- Resistance Level
- RIGL $19.80
- BGY $5.64
- Average True Range (ATR)
- RIGL 1.53
- BGY 0.08
- MACD
- RIGL -1.05
- BGY -0.04
- Stochastic Oscillator
- RIGL 3.66
- BGY 19.82
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BGY Blackrock Enhanced International Dividend Trust
Blackrock Enhanced International Dividend Trust has an investment objective to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its objectives by investing in equity securities of companies engaged in the energy and natural resources business and equity derivatives with exposure to the energy and natural resources industry.